Drug Trial Radar · NCT05822713
A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.
Last checked: Nov 20, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
516
Planned (sponsor's estimate)
Start
Apr 29, 2023
Primary completion
Aug 31, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A comparison of the efficacy of Amisulpride and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
Conditions
- PONV
Interventions
AmisulprideDrug
5mg/2ml
Amisulpride PlaceboDrug
2ml
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint was the composite measure complete responseTime frame: 24 hours after the end of surgery
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.